Cara Therapeutics (CARA) : During the past 4 weeks, traders have been relatively bearish on Cara Therapeutics (CARA), hence the stock is down -3.33% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -4.34% relative to the S&P 500. The 4-week change in the price of the stock is -2.96% and the stock has fallen -4.37% in the past 1 week.
Cara Therapeutics Inc. is up 1.9% in the last 3-month period. Year-to-Date the stock performance stands at -64.95%. The stock has recorded a 20-day Moving Average of 2.33% and the 50-Day Moving Average is 8.28%.
Cara Therapeutics (NASDAQ:CARA): The stock opened at $6.08 on Friday but the bulls could not build on the opening and the stock topped out at $6.20 for the day. The stock traded down to $5.75 during the day, due to lack of any buying support eventually closed down at $5.91 with a loss of -3.59% for the day. The stock had closed at $6.13 on the previous day. The total traded volume was 493,222 shares.
Also, Stifel Nicolaus maintains their rating on the shares of Cara Therapeutics (NASDAQ:CARA). The current rating of the shares is Buy. Equity Analysts at the Firm lowers the price target to $24 per share from $25 per share. The rating by the firm was issued on August 5, 2016.
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the bodys peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. CR845 is a peripherally-acting kappa opioid receptor agonist for the treatment of both acute and chronic pain. I.V. CR845 is an injectable version of its peripheral kappa opioid receptor agonist, which is designed to provide pain relief without stimulating mu opioid receptors. CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with these cannabinoid receptor subtypes, with no off-target activities.